Phase 1 Dose Escalation and Cohort Expansion Study Evaluating Safety, PK, PD and Clinical Activity of STC-15, a METTL3 Inhibitor in Patients with Advanced Malignancies, June 2024, ASCO Annual Meeting 2024

Justin C Moser1, Kyriakos P Papadopoulos2, Jordi Rodon Ahnert3, Yaara Ofir-Rosenfeld4, Josefin-Beate Holz4, STC15-22101 Study Team

1HonorHealth Research Institute; 2START San Antonio; 3The University of Texas MD Anderson Cancer Center; 4Storm Therapeutics LTD

Download poster